An international study involving 467 hospitals in 12 countries found that doctors do a good job of aggressively treating the early stages of heart attacks — even before laboratory tests confirm the diagnosis.
Barr Pharmaceuticals, Inc. confirmed that its subsidiary, Barr Laboratories, Inc., has initiated a patent challenge for Sanofi-Aventis U.S. LLC’s Ambien CR(R) (Zolpidem Tartrate Extended-Release Tablets), 6.25mg & 12.5mg.
Doctors at the University of Maryland Medical Center are using a new cryotherapy technique to treat cancerous and precancerous conditions of the esophagus.
A new clinical trial examines the effectiveness of a new vaccine designed to control the spread of cancer cells in people with Stage four kidney cancer.
Innovative pulmonary and PEGylation-based therapeutic product development is the focus of two new business units recently created at Nektar Therapeutics (Nasdaq: NKTR), the company announced today.
One in three ovarian cancer patients in the U.S. fails to receive the recommended comprehensive surgical treatment, according to a study in the May 15, 2007 issue of CANCER, a peer-reviewed journal of the American Cancer Society.
Genetic changes in the gene are responsible for around half of the most serious eczema cases, revealed by researchers at the University of Dundee in Scotland.
There is a new angle of attack on body acne in places that are hard-to-reach and treat, such as the back. ClindaReach?, a revolutionary easy to use treatment that packages a topical antibiotic with an ergonomically designed applicator to treat hard-to-reach acne, was launched this week by DUSA Pharmaceuticals, Inc. (NASDAQ GM: DUSA).
A new drug called Eslicarbazepine (ESL) shows promise as a treatment for epilepsy patients whose symptoms remain uncontrolled with existing medications.
In advanced cancer, anti-tumor therapies often work only partially or not at all, and tumors progress following treatment.